These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 33193349)
1. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. López-Reyes A; Martinez-Armenta C; Espinosa-Velázquez R; Vázquez-Cárdenas P; Cruz-Ramos M; Palacios-Gonzalez B; Gomez-Quiroz LE; Martínez-Nava GA Front Immunol; 2020; 11():570251. PubMed ID: 33193349 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. Ratajczak MZ; Kucia M Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300 [TBL] [Abstract][Full Text] [Related]
3. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. Zeng J; Xie X; Feng XL; Xu L; Han JB; Yu D; Zou QC; Liu Q; Li X; Ma G; Li MH; Yao YG EBioMedicine; 2022 Jan; 75():103803. PubMed ID: 34979342 [TBL] [Abstract][Full Text] [Related]
4. Macrophage Activation Syndrome in Coinciding Pandemics of Obesity and COVID-19: Worse than Bad. Engin AB; Engin ED; Engin A Adv Exp Med Biol; 2024; 1460():919-954. PubMed ID: 39287877 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2. Cheon SY; Koo BN Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684 [TBL] [Abstract][Full Text] [Related]
7. Targeting the NLRP3 Inflammasome in Severe COVID-19. Freeman TL; Swartz TH Front Immunol; 2020; 11():1518. PubMed ID: 32655582 [TBL] [Abstract][Full Text] [Related]
8. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection]. Chemarin M; Dufies O; Mazet A; Mellan E; Coudereau R; Py BF; Boyer L; Venet F Med Sci (Paris); 2022; 38(6-7):545-552. PubMed ID: 35766852 [TBL] [Abstract][Full Text] [Related]
9. Investigating the Nexus of NLRP3 Inflammasomes and COVID-19 Pathogenesis: Unraveling Molecular Triggers and Therapeutic Strategies. He Q; Hu D; Zheng F; Chen W; Hu K; Liu J; Yao C; Li H; Wei Y Viruses; 2024 Jan; 16(2):. PubMed ID: 38399989 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 induces "cytokine storm" hyperinflammatory responses in RA patients through pyroptosis. Zheng Q; Lin R; Chen Y; Lv Q; Zhang J; Zhai J; Xu W; Wang W Front Immunol; 2022; 13():1058884. PubMed ID: 36532040 [TBL] [Abstract][Full Text] [Related]
11. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Zhao N; Di B; Xu LL Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243 [TBL] [Abstract][Full Text] [Related]
12. Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention. Zhang J; Ma X; Liu F; Zhang D; Ling J; Zhu Z; Chen Y; Yang P; Yang Y; Liu X; Zhang J; Liu J; Yu P Front Immunol; 2023; 14():1203389. PubMed ID: 37868953 [TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45 Ratajczak MZ; Bujko K; Ciechanowicz A; Sielatycka K; Cymer M; Marlicz W; Kucia M Stem Cell Rev Rep; 2021 Feb; 17(1):266-277. PubMed ID: 32691370 [TBL] [Abstract][Full Text] [Related]
16. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. Yongzhi X Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Pan P; Shen M; Yu Z; Ge W; Chen K; Tian M; Xiao F; Wang Z; Wang J; Jia Y; Wang W; Wan P; Zhang J; Chen W; Lei Z; Chen X; Luo Z; Zhang Q; Xu M; Li G; Li Y; Wu J Nat Commun; 2021 Aug; 12(1):4664. PubMed ID: 34341353 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 targets the lysosome to mediate airway inflammatory cell death. Sun X; Yu J; Wong SH; Chan MTV; Zhang L; Wu WKK Autophagy; 2022 Sep; 18(9):2246-2248. PubMed ID: 35067165 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients. Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T Front Immunol; 2021; 12():629193. PubMed ID: 33732251 [TBL] [Abstract][Full Text] [Related]
20. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Saeedi-Boroujeni A; Mahmoudian-Sani MR; Nashibi R; Houshmandfar S; Tahmaseby Gandomkari S; Khodadadi A Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):247-258. PubMed ID: 34015982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]